TerraPower Isotopes Breaks Ground on the World’s Largest Actinium‑225 Manufacturing Facility in Philadelphia

Why Actinium‑225 Matters

Actinium‑225 (Ac‑225) is quickly becoming the "gold standard" in targeted alpha‑particle therapy (TAT). Its short‑range, high‑energy alpha particles can destroy cancer cells while sparing surrounding healthy tissue, offering hope for patients with metastatic prostate, breast, and pancreatic cancers.

TerraPower Isotopes’ Historic Milestone

On April 15, 2026, TerraPower Isotopes broke ground on what will be the world’s largest Actinium‑225 manufacturing facility, located in the University City district of Philadelphia. The 250,000‑square‑foot campus will house state‑of‑the‑art hot cells, purification lines, and a dedicated research wing.

Key Features of the New Plant

• Capacity: Designed to produce up to 1 millicurie of Ac‑225 per week – a ten‑fold increase over current global supply.
• Technology: Utilizes proprietary thorium‑232 target irradiation in a high‑flux reactor, followed by an automated radiochemical separation process.
• Safety: Equipped with redundant containment systems, real‑time radiation monitoring, and ISO‑14001 environmental management.
• Collaboration: Partnerships with the University of Pennsylvania, Jefferson Lab, and leading oncology centers for clinical trials.

Impact on the Oncology Landscape

The current global shortage of Ac‑225 limits patient access to TAT. TerraPower’s expanded production is expected to:

1. Reduce treatment costs by up to 40%.
2. Enable multi‑site clinical trials across North America and Europe.
3. Accelerate the development of next‑generation radiopharmaceuticals.

What This Means for Patients

With a reliable supply chain, oncologists can schedule Ac‑225 therapies more predictably, potentially improving survival rates for hard‑to‑treat cancers. Early data from Phase I trials already show a 70% reduction in tumor size with minimal side effects.

Economic and Regional Benefits

The Philadelphia project will create 300 high‑skill jobs and spur ancillary growth in the region’s biotech ecosystem. TerraPower has pledged a $50 million investment in local education programs to train the next generation of radiochemistry experts.

Looking Ahead

Construction is slated for completion in Q4 2027, with commercial production starting in early 2028. TerraPower Isotopes aims to set a new benchmark for isotopic supply chain resilience, positioning the United States as a global leader in medical isotope manufacturing.

Key Takeaways

• TerraPower Isotopes is building the world’s largest Ac‑225 facility.
• The plant will dramatically increase global supply, lowering costs and expanding patient access.
• Philadelphia will benefit from jobs, research collaborations, and educational investments.

Conclusion

The groundbreaking ceremony marks more than just a construction project—it signals a transformative shift in cancer treatment infrastructure. As the new facility comes online, patients, physicians, and investors alike can anticipate a brighter, more effective future for targeted alpha‑particle therapy.